Alfa Cytology

Alfa Cytology is a New York-based research solutions provider specializing in cancer therapeutics development and preclinical oncology studies. The company supports drug development from target discovery through IND application, offering integrated services designed to generate relevant evidence and streamline research. Its preclinical work includes drug efficacy studies, pharmacokinetic assessments, safety evaluations, cancer modeling, diagnostics development, and therapy development.

Alfa Cytology serves research across a broad range of cancer types, including breast, lung, gastrointestinal, blood, skin, and brain cancers. Its expertise also spans therapeutic targets and pathways such as immune checkpoints, cancer growth, protein kinases, autophagy, and tumor-associated macrophages, as well as approaches including small molecules, antibodies, cell and gene therapies, vaccines, peptides, nanomedicine, and oncolytic viruses.

The company’s modeling platforms include PrimePDX™, designed for clinical simulation, and Hu-Immune™, which provides humanized immune system mouse models. These platforms support configurable in vivo studies and immune-oncology research. Alfa Cytology also offers clinical research services and emphasizes scientific expertise, customized solutions, collaboration, and data security.